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Abstract p21-activated protein kinase Q-PAK phosphorylates
prolactin (PRL) in rat pituitary secretory granules on Ser-177
and on the equivalent site, Ser-179, in recombinant human PRL.
This is shown by comparison of phosphopeptide maps with the
human PRL mutant S179D. Q-PAK is present in rat and bovine
granules as identified by in-gel phosphorylation of histone H4,
and by immunoblotting. Thus, phosphorylation of PRL by
Q-PAK in granules produces the PRL molecule that has been
shown to antagonize the growth-promoting activity of unmodified
PRL, and is consistent with the identified role of Q-PAK in the
induction and maintenance of cytostasis. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Q-PAK (Pak2) is a ubiquitous member of the family of p21-
activated protein kinases (PAKs) which are activated by au-
tophosphorylation following binding of the GTP-bound form
of the small G-protein Cdc42 (for reviews see [1^5]). Q-PAK is
expressed ubiquitously, in contrast to K-PAK which is found
mainly in brain, but is also found in other tissues, and L-PAK
which is speci¢cally expressed in brain [1^5]. Q-PAK, but not
K-PAK or L-PAK, is activated by caspase cleavage during
apoptosis [6,7]. Both K- and Q-PAK are autophosphorylated
and activated in vivo and in vitro directly by sphingosine [8,9].
K- and Q-PAK are highly homologous but appear to have
di¡erent functions. K-PAK is involved in growth, as it is acti-
vated by growth factors [10,11] and insulin [12], and is in-
volved in the regulation of actin cytoskeletal reorganization
[13^16]. Q-PAK is activated in response to a variety of stimuli
that induce stress or lead to cytostasis or cell death, including
hyperosmolarity [17], DNA damaging drugs and UV and ion-
izing radiation [18]. Q-PAK appears to be involved in main-
taining cells in a non-dividing or cytostatic state [1,19].
Q-PAK phosphorylates a variety of proteins such as histones
4 and 2B, translation initiation factors, myosin light chain
from smooth muscle, myosin light chain kinase, myelin basic
protein, avian and Rous sarcoma virus nucleocapsid protein,
and Abelson tyrosine kinase (c-Abl) (for review see [1]). The
variety of substrates suggests the involvement of Q-PAK in the
regulation and possible coordination of cellular processes.
Regulation of biological functions by phosphorylation with
Q-PAK has been shown for c-Abl [20], smooth muscle myosin
light chain [21] and myosin light chain kinase [22], and Rous
sarcoma virus nucleocapsid protein [23,24]. Using synthetic
peptides as substrates, the recognition/phosphorylation deter-
minants have been identi¢ed as K/RRXS where X is prefera-
bly an acidic amino acid, such as glutamate or aspartate [25].
Prolactin (PRL) is a polypeptide hormone (23 kDa) in-
volved in maintaining normal reproductive functions as well
as regulation of growth (for reviews, see [26,27]). PRL exists
as multiple charged isoforms and is stored at high concentra-
tions (50 mM) in pituitary secretory granules as osmotically
inert structures [28,29]. Phosphorylation of PRL a¡ects its
biological functions [30,31] ; in two di¡erent PRL-responsive
cell lines, phosphorylated PRL has been shown to antagonize
the growth-promoting e¡ects of unmodi¢ed PRL [30,32]. The
major phosphorylation site in vivo in rat PRL is serine 177
[33] ; this corresponds to serine 179 in human and bovine PRL
[34]. A mutant of human prolactin (S179D), where serine 179
is mutated to aspartate to mimic phosphorylated serine, is a
highly e¡ective antagonist to unmodi¢ed PRL [35]. In addi-
tion, it has been shown that phosphorylated PRL autoregu-
lates PRL secretion in normal pituitary cells [36], and the
phosphorylation states of the hormone released from the pi-
tuitary change during the estrous cycle [37] and during preg-
nancy and pseudopregnancy [38].
Previous studies show that puri¢ed rat PRL is phosphory-
lated in vitro by Q-PAK (originally known as PAK I) [39]. The
in vivo phosphorylation site in rat PRL, serine 177/179 in the
sequence RRDSHK [33], is in a highly conserved region
among all PRLs [34] and contains the phosphorylation recog-
nition determinant for Q-PAK. Here, we report that Q-PAK is
present in rat and bovine pituitary secretory granules and
phosphorylates Ser-177/179. The data suggest that Q-PAK reg-
ulates the growth-promoting activity of PRL in vivo.
2. Materials and methods
2.1. Materials
Histone 4 and histone IIAS were from Roche Biochemicals; cyper-
methrin was from LC Laboratories. Antibodies which react speci¢-
cally with the regulatory domain of Q-PAK (N-19; SC 1872) or the
catalytic domain of the PAK isoforms (C-19; SC 1519), peroxidase-
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coupled secondary antibodies and protein A/G agarose were from
Santa Cruz Biotechnology. RR-1 anti-PAK antibody, which reacts
preferentially with endogenously activated Q-PAK [18], was obtained
as previously described [19]. Cellulose thin-layer chromatography
sheets were from Selecto Scienti¢c and silica gel thin-layer chromatog-
raphy sheets were from EM Science.
Glutathione S-transferase (GST)-Q-PAK obtained by expression of
the cDNA in insect cells (TN5B-4) was puri¢ed by binding to gluta-
thione-Sepharose 4B and released with glutathione or by cleavage
with thrombin as described previously [40]. GST-Cdc42 [41] and
wild-type human PRL and the S179D mutant [35] were expressed in
Escherichia coli and puri¢ed as described.
2.2. Isolation of prolactin secretory granules
Prolactin secretory granules from bovine and rat were obtained as
previously described [42,43]. Brie£y, the production of rat granules
involved homogenization in 0.32 M sucrose, removal of debris and
nuclei by low-speed centrifugation, pelleting of organelles by centri-
fugation for 30 min at 15 000Ug, and puromycin treatment of the
pellet which resulted in the detachment of ribosomes from rough
microsomes and lysis of contaminating growth hormone granules.
The puromycin-treated material was loaded onto discontinuous su-
crose gradients to yield a prolactin secretory granule fraction rela-
tively free of contaminants, as indicated by ultrastructural and bio-
chemical criteria [43]. The secretory granules were washed in high salt
to remove proteins adsorbed on the cytoplasmic face of the granules,
then pelleted in 0.32 M sucrose containing 5 mM MgCl2 and 1.0 M
KCl; the pellet was resuspended in 0.5 ml of 0.32 M sucrose solution.
As described earlier, two-dimensional polyacrylamide gel electropho-
resis and electron microscopic analyses of the subcellular fraction
served as controls for purity [43]. Analysis of 5P nucleotidase as a
plasma membrane marker, and succinate cytochrome c reductase as
a mitochondrial marker, demonstrated maximal contamination of
2.7% and 1.35%, respectively [44].
2.3. Phosphorylation of prolactin
In order to solubilize the limiting granule membrane and the pro-
teins and to monomerize the multimeric structure of PRL, secretory
granules (5^10 Wg) were pre-incubated at 37‡C for 50^60 min in 12 Wl
of bu¡er A (50 mM Tris^HCl, pH 7.5, 75 mM 2-mercaptoethanol, 7.5
mM ethylenediaminetetraacetic acid (EDTA), 0.02% Triton X-100)
containing protease inhibitors, aprotinin and leupeptin (0.17 mg/ml)
and the phosphatase inhibitor cypermethrin (0.4 WM). Phosphoryla-
tion of PRL (10^20 Wg of granule) was carried out in 30 Wl reaction
mixtures containing 20 mM Tris^HCl, pH 7.5, 8 mM MgCl2, 3 mM
EDTA, 30 mM 2-mercaptoethanol, 0.008% Triton X-100, 0.2 mM
[Q32P]ATP (2000 cpm/pmol), 0.16 WM cypermethrin, 0.07 mg/ml of
aprotinin and leupeptin, and GST-Q-PAK (0.2 Wg) activated with
Cdc42 (GTPQS) [40]. Incubation was for 30 min at 30‡C. Reactions
were terminated by addition of 10 Wl of 100 mM ATP and sodium
dodecyl sulfate (SDS) sample bu¡er. Following SDS polyacrylamide
gel electrophoresis (SDS^PAGE), phosphorylated proteins were de-
tected by autoradiography on X-ray ¢lm or with a phosphorimager.
Puri¢ed recombinant wild-type PRL and the mutant S179D (1.0 Wg)
were phosphorylated as described above, except that there was no pre-
incubation and Triton X-100 was omitted from bu¡er A.
2.4. Tryptic phosphopeptide mapping and phosphoamino acid analysis
Phosphorylated PRL was excised from SDS polyacrylamide gels
and extensively digested with trypsin and analyzed by two-dimension-
al phosphopeptide mapping and phosphoamino acid analysis [45].
2.5. Detection of Q-PAK activity by in-gel phosphorylation of histone
Proteins in PRL granules from rat (10 Wg) and bovine (20 Wg) were
separated on 10% polyacrylamide gels cast with 0.2 mg/ml of histone
IIAS; following electrophoresis, the proteins in the gel were denatured
and renatured and the protein kinase activity was assayed in-gel as
described [19].
2.6. Western blotting
Proteins in PRL granules from rat (10 Wg) and bovine (20 Wg)
pituitary glands were resolved by SDS^PAGE on a 10% gel and
were electrophoretically transferred to polyvinylidene £uoride mem-
branes. The membranes were blocked using 5% milk in Tris-bu¡ered
saline containing 0.1% Tween 20 and probed with antibodies (N-19 or
RR-1) which react speci¢cally with the regulatory domain of Q-PAK,
or C-19 which reacts preferentially with the catalytic domain of
Q-PAK as described previously [18,19]. Antibody binding was detected
using peroxidase-conjugated secondary antibodies and visualized with
ECL chemiluminescence reaction reagents.
3. Results
3.1. Q-PAK phosphorylates PRL on serine 177/179
To determine whether PRL in secretory granules was phos-
phorylated by Q-PAK, rat granules were pre-incubated in the
presence of Triton X-100, EDTA and reducing agent; this
opened the granule membrane, allowing access to [Q-32P]ATP,
solubilizing the semicrystalline proteins and converting the
multimeric structure of PRL into monomers. The solubilized
proteins were analyzed as substrates for Q-PAK by incubation
with [Q-32P]ATP and Mg2 in the presence or absence of ac-
tive Q-PAK. A low level of phosphorylation of rat PRL was
observed when the extract was incubated alone (Fig. 1A).
Upon addition of exogenous Q-PAK activated by preincuba-
tion with Cdc42(GTPQS), phosphorylation of PRL was in-
creased 15^20-fold over that observed with endogenous pro-
tein kinase(s).
Previously, Ser-179 was shown to be the phosphorylation
site involved in conferring antagonistic properties to phos-
phorylated human PRL, as compared to non-phosphorylated
PRL. To determine whether Q-PAK phosphorylated this site,
puri¢ed wild-type human PRL and the mutant S179D were
examined as substrates for Q-PAK; both were phosphorylated,
Fig. 1. Phosphorylation of PRL by Q-PAK. A: Solubilized protein
from rat secretory granules (5 Wg) was incubated with [Q-32P]ATP in
the presence or absence of activated GST-Q-PAK as described in
Section 2. B: Puri¢ed recombinant human PRL or the mutant
S179D (1.0 Wg) phosphorylated with GST-Q-PAK (0.2 Wg) in the
presence or absence of Cdc42 (GTPQS). The samples were analyzed
by SDS^PAGE and the radiolabeled proteins were detected by auto-
radiography.
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with 30^40% more phosphate incorporated into the wild-type
protein, as compared to the mutant (Fig. 1B). Phosphoamino
acid analysis showed only serine was phosphorylated in both
wild-type PRL and S179D (Fig. 2A). Tryptic phosphopeptide
mapping of wild-type PRL showed two major phosphopepti-
des. One of the phosphopeptides (spot 1) was missing in
S179D, identifying serine 179 as a site phosphorylated by
Q-PAK (Fig. 2B).
When solubilized PRL from rat granules was phosphorylat-
ed by exogenous Q-PAK, and the phosphorylation sites in
PRL were analyzed by tryptic phosphopeptide mapping,
only one tryptic phosphopeptide was observed (Fig. 2B).
This phosphopeptide migrated at the same position as the
tryptic phosphopeptide that contained phosphorylated Ser-
179 (spot 1). Since the sequences of the tryptic phosphopep-
tide containing Ser-179 in human PRL and Ser-177 in rat
PRL [34] are identical, we can conclude that Q-PAK phos-
phorylates Ser-177 in rat PRL.
3.2. Q-PAK is present in PRL secretory granules
To determine whether the secretory granules contained
Q-PAK, solubilized granule proteins were assayed for Q-PAK
activity using histone 4. Histone 4 has been shown to be a
speci¢c substrate for PAKs; they are the only serine/threonine
protein kinases reported to phosphorylate this substrate. His-
tone 4 was phosphorylated by a protein kinase in both bovine
and rat secretory granules (Fig. 3A). Addition of GST-Q-PAK
resulted in increased phosphorylation of histone 4 and of rat
PRL.
To determine the molecular weight of the histone 4 kinase,
in situ phosphorylation of histone cast into SDS polyacryl-
amide gels was carried out using rat and bovine secretory
granules, and puri¢ed recombinant Q-PAK. The protein kinase
activity corresponded to the same molecular weight (58^60
kDa) as the recombinant Q-PAK standard (Fig. 3B). It also
corresponded to the phosphoprotein bands in Fig. 3A which
migrated at 58^60 kDa (see arrow to Q-PAK) in the absence of
GST-Q-PAK. The in-gel protein kinase activity was stimulated
1.5-fold when the solubilized proteins from bovine granules
were preincubated with Cdc42(GTPQS) and ATP prior to
analysis by SDS^PAGE and autoradiography (Fig. 3C); acti-
vation by Cdc42 is a characteristic feature of PAKs. Thus,
Fig. 2. Identi¢cation of a phosphorylation site for Q-PAK in PRL. A: Phosphoamino acid analysis of human PRL and S179D phosphorylated
by Q-PAK. The positions of the phosphoamino acid standards are identi¢ed. B: Two-dimensional tryptic phosphopeptide mapping of wild-type
human PRL (left), S179D (middle) and PRL from rat granules (right) phosphorylated by exogenous Q-PAK. The 32P-labeled phosphoamino
acids and phosphopeptides were detected using a phosphorimager system.
Fig. 3. Detection of Q-PAK in Secretory Granules. A: Proteins from secretory granules from rat (5 Wg) or bovine (10 Wg) were solubilized and
assayed for Q-PAK activity using histone 4 as substrate. The samples were analyzed by SDS^PAGE on 15% gels, and the radiolabeled proteins
were detected by autoradiography. B: Solubilized protein from rat granules (10 Wg) or from bovine granules (20 Wg), and recombinant Q-PAK
(0.2 Wg), were analyzed by in situ phosphorylation of histone following SDS^PAGE on 10% polyacrylamide, as described in Section 2. Q-PAK
activity was detected by autoradiography. C: Solubilized protein from bovine granules (20 Wg) and recombinant Q-PAK were incubated with
Cdc42(GTPQS) and ATP prior to analysis by in situ phosphorylation of histone. D: Solubilized proteins from rat (10 Wg) and bovine (20 Wg)
secretory granules were immunoblotted with antibodies N-19 and RR-1, which react speci¢cally with the regulatory domain of Q-PAK, and C-
19 which reacts with the highly conserved catalytic domain of the three PAK proteins. Detection was carried out with horseradish peroxidase-
linked secondary antibodies and ECL reagents.
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preactivation enhanced phosphorylation of histone in the gel,
indicating both active and inactive forms of Q-PAK were
present in the granule. Since K- and L-PAK migrate at 68
and 65 kDa on SDS^PAGE, respectively, these forms of
PAK were not present in any signi¢cant amounts in the gran-
ules.
Further con¢rmation of the identity of the protein kinase in
PRL granules was provided by immunoblotting studies with
antibodies speci¢c for Q-PAK. A protein migrating at the same
molecular weight as Q-PAK (58^60 kDa) was immunoreactive
with antibodies speci¢c for the N-terminus of Q-PAK, N-19
and RR-1. With N-19 antibody, multiple bands were detected,
re£ecting the multiple phosphorylated forms of Q-PAK [18].
C-19, prepared to the conserved catalytic domain of the
PAKs, reacted only with protein migrating at 58 kDa, sup-
porting the ¢nding in Fig. 3C that K- and L-PAK were not
present in the granule preparation.
4. Discussion
The biological activity of PRL has previously been shown
to be regulated, in part, by the state of phosphorylation
[30,42]. Non-phosphorylated PRL promotes growth, while
phosphorylated PRL induces cytostasis. The major phosphor-
ylation site in PRL is Ser-177/179 [33,34]. Here we show that
Q-PAK is present in secretory granules and both endogenous
and exogenous Q-PAK phosphorylate PRL on Ser-177/179.
Phosphorylation of PRL from secretory granules is more
e¡ective when the membrane is disrupted with Triton X-100,
metal ions are chelated by EDTA and intermolecular bridges
are disrupted by reducing agents; these aid in the formation
of monomers from the multimeric semi-crystalline PRL
[25,46]. PRL is also phosphorylated in secretory granule ex-
tracts by the endogenous protein kinase that has been identi-
¢ed as Q-PAK using a variety of methods. These include phos-
phorylation of the PAK-speci¢c substrate histone 4, migration
of the protein kinase activity at 58^60 kDa by an in-gel kinase
assay, Western blotting with antibody speci¢c for Q- PAK and
activation of the endogenous protein kinase by Cdc42.
Recombinant human PRL is phosphorylated by Q-PAK at
two sites as determined by tryptic phosphopeptide mapping.
One of the phosphorylation sites is Ser-179 in phosphopeptide
1, as deduced from the disappearance of phosphopeptide 1
when the mutant S179D is phosphorylated by Q-PAK. The
identity of phosphopeptide 2 is not known at this time.
Only one major phosphopeptide is observed when PRL
from rat secretory granules is phosphorylated by Q- PAK.
The migration of this phosphopeptide is identical to the phos-
phopeptide that contains Ser-179 in human PRL; thus it can
be concluded that rat PRL is phosphorylated speci¢cally on
Ser-177 by Q-PAK. Ser-177/179 is in the sequence RRDSHK
that contains the recognition/phosphorylation determinant for
Q-PAK [27]. Protein kinase A has been shown to phosphory-
late this same site in rat PRL [33], although large amounts of
the enzyme are needed to e¡ect signi¢cant phosphorylation.
The reported sequence for Q-PAK contains no signal se-
quence that would automatically place it in the secretory path-
way and eventually into secretory granules. Since the vast
majority of Q-PAK is cytosolic [17,18], this is to be expected.
However, it is unlikely that the Q-PAK activity observed in the
granules is the result of contamination by cytoplasmic Q-PAK
for three reasons: (1) preparation of the granules involves a
high salt wash with 1 M KCl; (2) previous studies have dem-
onstrated that solubilization of the granule membrane, the
material to which cytosolic Q-PAK could adhere during gran-
ule isolation, does not eliminate PRL kinase activity in the
granules [43]; (3) there is a possibility that PAK in granules is
N-glycosylated, since treatment with a deglycosylation en-
zyme, puri¢ed peptide-N4-(N-acetyl-L-glucosaminyl)-aspara-
gine amidase (PNGase F) [47], results in a decrease in molec-
ular weight (data not shown). N-Glycosylation is a
posttranslational modi¢cation which only occurs within the
secretory pathway.
The question remains therefore as to how Q-PAK ¢nds its
way into the secretory granule to e¡ect phosphorylation of
PRL. There are several known mechanisms whereby proteins
translated on free ribosomes can cross membranes after syn-
thesis. Likely possibilities include the TAP protein mecha-
nisms for cytosol to endoplasmic reticulum cisternal space
import (for review see [48]) and the ABC-ATPase system,
variants of which can move proteins from the cytosol into
membrane-bound compartments in the cell, or can move
them out of the cell through the plasma membrane [49]. Al-
ternatively, it remains possible that a di¡erentially spliced
mRNA may be produced in the pituitary (as a minor species)
which encodes a version with a signal sequence. Interestingly,
protein kinase A and protein kinase C have been shown to be
present in anterior pituitary granules [50], although they also
do not contain a signal sequence.
The phosphorylated and non-phosphorylated forms of PRL
have been shown to have di¡erent e¡ects on cell growth.
Phosphorylation at Ser-177/179 has a major e¡ect on biolog-
ical activity; it not only eliminates the growth-promoting
qualities of PRL, but antagonizes the growth-promoting e¡ect
of unmodi¢ed PRL. For example, we recently showed that
unmodi¢ed PRL can be an autocrine growth factor in human
prostate cancer cells, and that the mimic of phosphorylated
PRL (S179D) interrupts growth in vivo [51]. The data herein
suggest that Q-PAK may retard growth in these and perhaps
other cells via phosphorylation of PRL at Ser-177/179. Q-PAK
has been shown to have cytostatic properties (as reviewed in
[1]). It is interesting to note that apoptotic stimuli also activate
Q-PAK and that S179D promotes apoptosis in the lung and
thymus of exposed rat pups [52].
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